Tenure track position at ASU

Tenure track position at ASU

The Center for Evolution & Medicine (CEM) and the School of Life Sciences (SOLS) at Arizona State University (ASU) invite applications for a full time open-rank, tenured or tenure-track faculty position. Rank and tenure status will be commensurate with experience. The anticipated start date is August 2019.   JOB# 12629

Preferred research topics include immunology, inflammation or autoimmune disease. Other possible topics include research on physiological systems, infectious disease, or aging. All approaches are welcome including field, clinical, and/or lab-based research. Clinical relevance and potential collaborations in clinical settings are encouraged. Preference will be given to candidates whose research plans hold promise of major advances that demonstrate why evolutionary biology is essential for medicine or public health. Experience or an interest in teaching evolutionary medicine and otherwise contributing to developing the field is desired.

This position is part of an institutional initiative to advance the field of evolutionary medicine. Under the direction of Randolph Nesse, the Center for Evolution & Medicine (CEM) seeks to improve human health by establishing evolutionary biology as a basic science for medicine, worldwide. In an institution that rewards transdisciplinary research and innovation, the CEM currently includes faculty members from the School of Life Sciences, School of Human Evolution and Social Change, the Department of Psychology, and the School of Mathematical and Statistical Sciences, as well as researchers from ASU’s Complex Adaptive Systems Initiative and clinical partnerships with the Mayo Clinic and Banner Hospitals. For more information on the CEM, please visit http://evmed.asu.edu/.

Newly remodeled space for CEM offices and laboratories encourages collaborations between members of its highly interdisciplinary group. The CEM provides support for visiting speakers, workshops, research collaborations, and extensive web resources for the world’s evolution and medicine community.

The successful candidate will be expected to develop or maintain an innovative, independent, extramurally funded research program, provide excellent classroom instruction, contribute to curriculum development, mentor students and postdoctoral fellows, interact with a transdisciplinary group of colleagues, and provide service to the department, college and university. A competitive start-up package will be provided.

Minimum Qualifications: a doctoral degree or an MD by the time of appointment, and a track record of research that uses evolutionary biology to address questions about health and disease. Candidates for rank of Associate or Full Professor must have a demonstrated record of significant extramural funding.

Desired Qualifications: postdoctoral experience, publications in refereed journals, demonstrated excellence in teaching and/or mentoring, experience working in a transdisciplinary environment; demonstrated success meeting the needs of diverse student populations and/or reaching out to diverse communities.

To apply, please submit the following materials within a single PDF document to solsfacultysearch5@asu.edu:

(1) a cover letter that specifies the rank for which you seek consideration and why this position is a good fit for you, (2) curriculum vitae, (3) three representative publications, (4) a statement of research vision and plans, (5) a statement of teaching philosophy/experience and (6) contact information (name, email and telephone number) for three references. Only electronic applications will be considered.

The initial closing date for receipt of complete applications is December 7, 2018; if not filled, review will continue every week thereafter until the search is closed. A background check is required for employment. For additional information, please feel free to contact Randolph Nesse (nesse@asu.edu) or James Collins (jcollins@asu.edu).

Arizona State University is a VEVRAA Federal Contractor and an Equal Opportunity/Affirmative Action Employer. All qualified applicants will be considered without regard to race, color, sex, religion, national origin, disability, protected veteran status, or any other basis protected by law. ASU’s full non-discrimination statement (ACD 401) is located on the ASU website athttps://www.asu.edu/aad/manuals/acd/acd401.html and https://www.asu.edu/titleIX

Did natural selection build in adaptive therapy for cancer?

Did natural selection build in adaptive therapy for cancer?

A new article proposes that adaptive therapy for cancer has been there all along as one of the body’s ways of preventing cancer. 

Thomas, F., Donnadieu, E., Charriere, G. M., Jacqueline, C., Tasiemski, A., Pujol, P., … Ujvari, B. (2018). Is adaptive therapy natural? PLOS Biology, 16(10), e2007066. https://doi.org/10.1371/journal.pbio.2007066

Abstract: Research suggests that progression-free survival can be prolonged by integrating evolutionary principles into clinical cancer treatment protocols. The goal is to prevent or slow the proliferation of resistant malignant cell populations. The logic behind this therapy relies on ecological and evolutionary processes. These same processes would be available to natural selection in decreasing the probability of an organism’s death due to cancer. We propose that organisms’ anticancer adaptions include not only ones for preventing cancer but also ones for directing and retarding the evolution of life-threatening cancer cells. We term this last strategy natural adaptive therapy (NAT). The body’s NAT might include a lower than otherwise possible immune response. A restrained immune response might forego maximum short-term kill rates. Restraint would forestall immune-resistant cancer cells and produce long-term durable control of the cancer population. Here, we define, develop, and explore the possibility of NAT. The discovery of NAT mechanisms could identify new strategies in tumor prevention and treatments. Furthermore, we discuss the potential risks of immunotherapies that force the immune system to ramp up the short-term kill rates of malignant cancer cells in a manner that undermines the body’s NAT and accelerates the evolution of immune resistance.

Cancer transmission via the placenta

Cancer transmission via the placenta

Greaves M, Hughes W. Cancer cell transmission via the placenta. Evolution, Medicine, and Public Health. 2018 Jan 1;2018(1):106–15. (open access

Abstract: Cancer cells have a parasitic propensity in the primary host but their capacity to transit between individuals is severely restrained by two factors: a lack of a route for viable cell transfer and immune recognition in allogeneic, secondary recipients. Several examples of transmissible animal cancers are now recognised. In humans, the only natural route for transmission is via the haemochorial placenta which is permissive for cell traffic. There are three special examples of this occurring in utero: maternal to foetus, intraplacental twin to twin leukaemias and choriocarcinoma-extra-embryonic cells to mother. We discuss the rare circumstances under which such transmission occurs.

Influenza and One Health 100 years after the Epidemic

Influenza and One Health 100 years after the Epidemic

Bailey, E. S., Choi, J. Y., Fieldhouse, J. K., Borkenhagen, L. K., Zemke, J., Zhang, D., & Gray, G. C. (2018). The continual threat of influenza virus infections at the human–animal interface. Evolution, Medicine, and Public Health, 2018(1), 192–198. https://doi.org/10.1093/emph/eoy013

Abstract: This year, in 2018, we mark 100 years since the 1918 influenza pandemic. In the last 100 years, we have expanded our knowledge of public health and increased our ability to detect and prevent influenza; however, we still face challenges resulting from these continually evolving viruses. Today, it is clear that influenza viruses have multiple animal reservoirs (domestic and wild), making infection prevention in humans especially difficult to achieve. With this report, we summarize new knowledge regarding influenza A, B, C and D viruses and their control. We also introduce how a multi-disciplinary One Health approach is necessary to mitigate these threats. 1. Bailey ES, Choi JY, Fieldhouse JK, Borkenhagen LK,